Tag Archives: Gilead

Gilead Tops the BusinessWeek 50

The best-performing company of them all? Well, according to BusinessWeek, it’s a biopharmaceutical company, Gilead Sciences, which placed first in the annual BusinessWeek 50. The company posted some impressive numbers: a 48.6 percent pretax profit as a percentage of average invested capital (taken as an average of the last three years), 38.2 average annual sales [...]
Posted in Strategy | Also tagged | Leave a comment

Gilead Buys CV Therapeutics (Update 1)

The morning’s other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that it will purchase CV Therapeutics for $1.4 billion. The sudden move frees Palo Alto-based cardiovascular company CV Therapeutics from the hostile embrace of Astellas Pharma, ending a messy $1.1 billion takeover attempt. With the acquisition, Gilead, [...]
Posted in Deals | Also tagged , , , , , , | 1 Comment

Gilead Making a Bundle

Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech [...]
Posted in Biotech, Emerging Markets, R&D | Also tagged , , | Leave a comment